Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.

Beaver JA, Hazarika M, Mulkey F, Mushti S, Chen H, He K, Sridhara R, Goldberg KB, Chuk MK, Chi DC, Chang J, Barone A, Balasubramaniam S, Blumenthal GM, Keegan P, Pazdur R, Theoret MR.

Lancet Oncol. 2018 Feb;19(2):229-239. doi: 10.1016/S1470-2045(17)30846-X. Epub 2018 Jan 18.


Challenges in Opening and Enrolling Patients in Clinical Trials.

Vose JM, Chuk MK, Giles F.

Am Soc Clin Oncol Educ Book. 2017;37:139-143. doi: 10.14694/EDBK_179807. Review.


Clinical trial enrollment of adolescents and young adults with sarcoma.

Davis LE, Janeway KA, Weiss AR, Chen YE, Scharschmidt TJ, Krailo M, Glade Bender JL, Kopp LM, Patel SR, Schwartz GK, Horvath LE, Hawkins DS, Chuk MK, Reinke DK, Gorlick RG, Randall RL.

Cancer. 2017 Sep 15;123(18):3434-3440. doi: 10.1002/cncr.30757. Epub 2017 May 11. Review.


FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.

Osgood CL, Chuk MK, Theoret MR, Huang L, He K, Her L, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Nov 1;23(21):6384-6389. doi: 10.1158/1078-0432.CCR-16-2422. Epub 2017 Feb 27.


FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.

Chuk MK, Chang JT, Theoret MR, Sampene E, He K, Weis SL, Helms WS, Jin R, Li H, Yu J, Zhao H, Zhao L, Paciga M, Schmiel D, Rawat R, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Oct 1;23(19):5666-5670. doi: 10.1158/1078-0432.CCR-16-0663. Epub 2017 Feb 24.


U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.

Hazarika M, Chuk MK, Theoret MR, Mushti S, He K, Weis SL, Putman AH, Helms WS, Cao X, Li H, Zhao H, Zhao L, Welch J, Graham L, Libeg M, Sridhara R, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Jul 15;23(14):3484-3488. doi: 10.1158/1078-0432.CCR-16-0712. Epub 2017 Jan 13.


Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents.

Chuk MK, Mulugeta Y, Roth-Cline M, Mehrotra N, Reaman GH.

Clin Cancer Res. 2017 Jan 1;23(1):9-12. doi: 10.1158/1078-0432.CCR-16-1367. Epub 2016 Oct 25.


Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.

Theoret MR, Pai-Scherf LH, Chuk MK, Prowell TM, Balasubramaniam S, Kim T, Kim G, Kluetz PG, Keegan P, Pazdur R.

Clin Cancer Res. 2015 Oct 15;21(20):4545-51. doi: 10.1158/1078-0432.CCR-14-3244.


Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, Merino MJ, Lodish M, Dombi E, Steinberg SM, Wells SA, Balis FM.

Clin Cancer Res. 2013 Aug 1;19(15):4239-48. doi: 10.1158/1078-0432.CCR-13-0071. Epub 2013 Jun 13.


A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.

Chuk MK, Aikin A, Whitcomb T, Widemann BC, Zannikos P, Bayever E, Balis FM, Fox E.

Pediatr Blood Cancer. 2012 Nov;59(5):865-9. doi: 10.1002/pbc.24201. Epub 2012 Jul 27.


A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.

Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, Goodwin A, Kromplewski M, Jayaprakash N, Marotti M, Brown KH, Wenrich B, Adamson PC, Widemann BC, Balis FM.

J Clin Oncol. 2010 Dec 10;28(35):5174-81. doi: 10.1200/JCO.2010.30.9674. Epub 2010 Nov 8.


Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model.

Chuk MK, Cole DE, McCully C, Loktionova NA, Pegg AE, Parker RJ, Pauly G, Widemann BC, Balis FM, Fox E.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1291-7. doi: 10.1007/s00280-010-1407-9. Epub 2010 Aug 20.



Chuk MK, Balis FM, Fox E.

Oncologist. 2009 Aug;14(8):794-9. doi: 10.1634/theoncologist.2009-0104. Epub 2009 Aug 14. Review. No abstract available. Erratum in: Oncologist. 2009 Sep;14(9):949.


Discordance of MLL-rearranged (MLL-R) infant acute lymphoblastic leukemia in monozygotic twins with spontaneous clearance of preleukemic clone in unaffected twin.

Chuk MK, McIntyre E, Small D, Brown P.

Blood. 2009 Jun 25;113(26):6691-4. doi: 10.1182/blood-2009-01-202259. Epub 2009 May 1.


Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients.

Kim SY, Dabb AA, Glenn DJ, Snyder KM, Chuk MK, Loeb DM.

Pediatr Blood Cancer. 2008 Apr;50(4):779-83.

Supplemental Content

Support Center